Biotech Values

[DewDiligence]

CHMP approves VPHM’s Cinryze for prophylaxis and acute treatment of HAE, including self administration:

http://finance.yahoo.com/news/ViroPharma-Announces-Positive-prnews-3962393730.html?x=0&.v=1

In the US, Cinryze was approved for prophylaxis in Oct 2008 (#msg-32795311); however, Cinryze for the acute indication is blocked by CSL’s Berinert, which has marketing exclusivity until 2016 stemming from an orphan designation and FDA approval in Oct 2009 (#msg-42409618).